LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,977
تعداد دریافت فایل اصل مقاله11,291,618
Sadeghian, Sara, Zare, Fateme, Saghaie, Lotfollah, Sabet, Razieh. (1402). Synthesis of Deferiprone as a Widely Used Iron-Chelating Drug for the Treatment of Iron-Overload Diseases. سامانه مدیریت نشریات علمی, 10(1), 77-82. doi: 10.30476/tips.2024.102338.1236
Sara Sadeghian; Fateme Zare; Lotfollah Saghaie; Razieh Sabet. "Synthesis of Deferiprone as a Widely Used Iron-Chelating Drug for the Treatment of Iron-Overload Diseases". سامانه مدیریت نشریات علمی, 10, 1, 1402, 77-82. doi: 10.30476/tips.2024.102338.1236
Sadeghian, Sara, Zare, Fateme, Saghaie, Lotfollah, Sabet, Razieh. (1402). 'Synthesis of Deferiprone as a Widely Used Iron-Chelating Drug for the Treatment of Iron-Overload Diseases', سامانه مدیریت نشریات علمی, 10(1), pp. 77-82. doi: 10.30476/tips.2024.102338.1236
Sadeghian, Sara, Zare, Fateme, Saghaie, Lotfollah, Sabet, Razieh. Synthesis of Deferiprone as a Widely Used Iron-Chelating Drug for the Treatment of Iron-Overload Diseases. سامانه مدیریت نشریات علمی, 1402; 10(1): 77-82. doi: 10.30476/tips.2024.102338.1236

Synthesis of Deferiprone as a Widely Used Iron-Chelating Drug for the Treatment of Iron-Overload Diseases

Trends in Pharmaceutical Sciences
مقاله 8، دوره 10، شماره 1، خرداد 2024، صفحه 77-82    اصل مقاله (397.8 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.30476/tips.2024.102338.1236
نویسندگان
Sara Sadeghian1؛ Fateme Zare2؛ Lotfollah Saghaie3؛ Razieh Sabet* 1
1Department of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
2Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Medicinal Chemistry, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
چکیده
Thalassemia is a genetic disease that significantly affects human health. The common treatment of thalassemia is the regular injection of red blood cell, which is associated with the accumulation of iron in different tissues of the body, and makes chelation therapy necessary. Deferiprone and deferoxamine are broadly used as iron chelating agents in the vast majority of thalassemia cases. In this study, an efficient method for the synthesis of deferiprone was used by reacting maltol with methylamine in a mixture of water and ethanol as solvent. The structure of deferiprone was assigned using different spectroscopic techniques such as IR, 1H-NMR, and 13C-NMR. The advantages of this pathway are simple, practical, one-pot cascade, mild condition and high yield. The statistics of the Ministry of Health of Iran show the growing trend of deferiprone drug consumption in the country. Therefore, the domestic preparation of this drug can help the pharmaceutical industry in order to reduce costs and make it available for target patients.
Keywords: Synthesis, Deferiprone, Maltol, Methylamine, Iron chelating agent.

تازه های تحقیق

Razieh Sabet (Google Scholar)

کلیدواژه‌ها
Synthesis؛ Deferiprone؛ Maltol؛ Methylamine؛ Iron chelating agent
مراجع
1.    Kontoghiorghes GJ, Kleanthous M, Kontoghiorghe CN. The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia. Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020011. doi: 10.4084/MJHID.2020.011. PMID: 31934321; PMCID: PMC6951358.
2.    Binding A, Ward R, Tomlinson G, Kuo KHM. Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload. Eur J Haematol. 2019 Aug;103(2):80-87. doi: 10.1111/ejh.13244. Epub 2019 May 30. PMID: 31066943.
3.    Hider RC, Hoffbrand AV. The Role of Deferiprone in Iron Chelation. N Engl J Med. 2018 Nov 29;379(22):2140-2150. doi: 10.1056/NEJMra1800219. PMID: 30485781.
4.    Klopstock T, Tricta F, Neumayr L, Karin I, Zorzi G, Fradette C, et al. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol. 2019 Jul;18(7):631-642. doi: 10.1016/S1474-4422(19)30142-5. PMID: 31202468.
5.    Timoshnikov VA, Kobzeva TV, Polyakov NE, Kontoghiorghes GJ. Redox Interactions of Vitamin C and Iron: Inhibition of the Pro-Oxidant Activity by Deferiprone. Int J Mol Sci. 2020 May 31;21(11):3967. doi: 10.3390/ijms21113967. PMID: 32486511; PMCID: PMC7312906.
6.    Elalfy MS, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Kanter J, et al. Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years. Blood Adv. 2023 Feb 28;7(4):611-619. doi: 10.1182/bloodadvances.2021006778. PMID: 36018224; PMCID: PMC9979751.
7.    Kontoghiorghes GJ. Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. Int J Mol Sci. 2022 Jun 16;23(12):6735. doi: 10.3390/ijms23126735. PMID: 35743183; PMCID: PMC9223898.
8.    Flores Martin A, Shanmugarajah P, Hoggard N, Hadjivassiliou M. Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review. Cerebellum. 2021 Jun;20(3):454-461. doi: 10.1007/s12311-020-01222-7. Epub 2021 Jan 6. PMID: 33409768; PMCID: PMC8213658.
9.    Fassihi A, Abedi D, Saghaie L, Sabet R, Fazeli H, Bostaki G, et al. Synthesis, antimicrobial evaluation and QSAR study of some 3-hydroxypyridine-4-one and 3-hydroxypyran-4-one derivatives. Eur J Med Chem. 2009 May;44(5):2145-57. doi: 10.1016/j.ejmech.2008.10.022. Epub 2008 Oct 30. PMID: 19056147.
10.    Hassani B, Zare F, Emami L, Khoshneviszadeha M, Fazel R, Kave N, et al., Synthesis of 3-hydroxypyridin-4-one derivatives bearing benzyl hydrazide substitutions towards anti-tyrosinase and free radical scavenging activities. RSC Adv. 2023 Sept; 13(46):32433-32443. doi: 10.1039/D3RA06490E.
11.    Sadeghian S, Zare F, Goshtasbi G, Fassihi A, Saghaie L, Zare P, et al., Synthesis, Antimicrobial Evaluation, Molecular Docking, and ADME Studies of Some Novel 3‐Hydroxypyridine‐4‐one Derivatives. ChemistrySelect. 2023 Nov 24;8(44):e202302408. doi: 10.1002/slct.202302408.

آمار
تعداد مشاهده مقاله: 53,791
تعداد دریافت فایل اصل مقاله: 415


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب